Psychedelics

Ispire And IKE Tech Advance FDA-Backed Age Verification Tech To Curb Youth Vaping
Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Medical Cannabis And Legal Cocaine: The Unusual Permit That Puts Border Laws In Check
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

Psychedelics Recent News

New Study Charts Adverse Events In Psychedelic-Assisted Therapies
New framework introduces comprehensive guidelines for assessing side effects in psychedelic-assisted therapies, aiming to enhance safety and patient care.
Mike Tyson On Psychedelics: 'The Toad Showed Me God, And It Changed My Life'
Mike Tyson shares how 5-MeO-DMT helped him find peace, confront fears, and embrace a new perspective on life.
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.
High Tide Closes Final Tranche Of $15M Debt, Plans Retail Growth
High Tide Inc. closes final tranche of $15M debt facility, enhancing financial strength for retail expansion and debt repayment.
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Cybin starts Phase 3 trials for its depression treatment, CYB003, backed by strong Phase 2 data and a solid cash position.
DEA Faces Lawsuit Alleging Bias In Marijuana Rescheduling Process
Researcher David Heldreth sues DEA over alleged legal violations in marijuana rescheduling, citing bias and exclusion of small businesses and Native American tribes.
Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments
Recent patents on novel psychedelic prodrugs show promise in enhancing stability and efficacy, offering new hope for effective mental health treatments.
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M.
Relaxation Emerges As Strongest Predictor Of Psychedelic Therapy Benefits, Study
Study reveals relaxation, not mystical experiences, as the main factor in the success of psychedelic therapy for treatment-resistant depression.
U.S. Election Stress Fuels Demand For Psychedelic-Assisted Therapy
Post-election stress has driven a surge in Americans seeking psychedelic therapy for relief, with clinics reporting record appointments.
Psychedelic Mushrooms Market Poised For $3.3 Billion Surge By 2031
Psychedelic mushrooms market to reach $3.3 billion by 2031, due to rising demand, regulatory changes & growing psilocybin acceptance.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved